BRANCHAMIN 4%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BRANCHAMIN 4% (BRANCHAMIN 4%).
Provides essential branched-chain amino acids (leucine, isoleucine, valine) to correct deficiencies and support protein synthesis in catabolic states; serves as a substrate for energy production and muscle metabolism.
| Metabolism | Metabolized via transamination and oxidation pathways; primarily metabolized in skeletal muscle and liver; not significantly metabolized by CYP450 enzymes. |
| Excretion | Primarily renal; >90% of infused amino acids are excreted in urine as metabolites (urea, ammonia) within 24 hours; minimal biliary/fecal elimination (<5%) |
| Half-life | Terminal elimination half-life of individual amino acids ranges from 0.5 to 2 hours; clinical context: rapid clearance requires continuous infusion to maintain plasma levels |
| Protein binding | Negligible (<5%); amino acids are largely unbound in plasma; transported via specific carrier proteins but not significantly protein-bound |
| Volume of Distribution | 0.3–0.5 L/kg; clinical meaning: distributes mainly into extracellular fluid, reflecting rapid equilibration with lean body tissues |
| Bioavailability | Intravenous: 100% (administered as IV infusion); not available orally; enteral absorption would be subject to first-pass metabolism and variable, thus not clinically used |
| Onset of Action | Intravenous: immediate metabolic effect within 5–15 minutes; clinical effect (nitrogen balance improvement) observed within 1–2 hours of starting infusion |
| Duration of Action | 2–4 hours post-infusion; clinical note: effects on protein synthesis persist for 4–6 hours, necessitating continuous or intermittent infusion to maintain anabolic state |
1-1.5 g/kg/day intravenously, infused at a rate not exceeding 10 g/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh Class B: reduce dose by 50%; Class C: contraindicated. |
| Pediatric use | 0.5-2 g/kg/day intravenously, adjusted based on age and clinical status. |
| Geriatric use | Start at lower end of dosing range (0.8 g/kg/day) due to decreased renal function; monitor fluid balance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BRANCHAMIN 4% (BRANCHAMIN 4%).
| Breastfeeding | Excreted in breast milk in low amounts. M/P ratio not established. Generally considered compatible with breastfeeding. |
| Teratogenic Risk | No known teratogenic risk. Branched-chain amino acids are endogenous substances; no fetal harm reported. Trimester-independent low risk. |
| Fetal Monitoring | Monitor maternal ammonia levels, electrolytes, and liver function. Fetal assessment per standard obstetric care. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component; severe hepatic failure with risk of hepatic coma; maple syrup urine disease; uncontrolled metabolic acidosis.
| Precautions | Monitor fluid and electrolyte balance; risk of hyperammonemia in hepatic impairment; use with caution in patients with metabolic acidosis or hypersensitivity to amino acids. |
| Food/Dietary | No direct food interactions. However, oral protein intake should be tailored to liver disease severity; avoid excessive protein that may exacerbate hyperammonemia. Administer IV only, separate from enteral nutrition. Use with caution in patients with phenylketonuria as product contains phenylalanine. |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility. No human studies available; animal studies not suggestive of impairment. |
| Clinical Pearls |
| BRANCHAMIN 4% is a branched-chain amino acid (BCAA) solution used in parenteral nutrition for patients with hepatic encephalopathy or severe liver disease. Monitor serum ammonia levels closely; BCAA therapy may precipitate hyperammonemia in patients with urea cycle disorders. Do not administer via peripheral vein due to high osmolarity (approx. 840 mOsm/L); use central line only. In hepatic encephalopathy, aim to provide 0.8-1.2 g amino acids/kg/day, titrating to protein tolerance. |
| Patient Advice | This medication is given through a central vein (large vein) in your chest or neck, not through a small vein in your arm. · Tell your healthcare provider immediately if you experience confusion, drowsiness, or difficulty waking up, as these may be signs of ammonia buildup. · You will need regular blood tests to monitor ammonia levels and liver function during treatment. · Do not change the infusion rate or stop the infusion without consulting your doctor. · Report any signs of infection at the catheter site (redness, swelling, pain, or drainage). |